Change over time in ability to perform activities of daily living in myotonic dystrophy type 1 by Landfeldt, Erik et al.
Vol.:(0123456789) 
Journal of Neurology 
https://doi.org/10.1007/s00415-020-09970-6
ORIGINAL COMMUNICATION
Change over time in ability to perform activities of daily living 
in myotonic dystrophy type 1
Erik Landfeldt1  · Nikoletta Nikolenko2 · Cecilia Jimenez‑Moreno3,4 · Sarah Cumming5 · Darren G. Monckton5 · 
Catharina G. Faber6 · Ingemar S. J. Merkies6,7 · Grainne Gorman8 · Chris Turner2,9 · Hanns Lochmüller10,11
Received: 17 February 2020 / Revised: 25 May 2020 / Accepted: 1 June 2020 
© The Author(s) 2020
Abstract
Objective The objective of this longitudinal, observational study was to investigate change over time in ability to perform 
activities of daily living in myotonic dystrophy type 1 (DM1).
Methods Adults with genetically confirmed DM1 were recruited as part of the PhenoDM1 study in the UK. Data on activi-
ties of daily living were recorded through the DM1-ActivC at baseline and a follow-up visit after 12 (± 3) months. A subset 
of patients had advanced genetic testing to determine the size of the progenitor allele.
Results Our sample comprised 150 patients with DM1 (mean age: 45 years; 52% female). Mean follow-up was 383 days. 
Mean DM1-ActivC total score at baseline was 71.24 (95% confidence interval 67.77–74.71) and at the follow-up visit 69.04 
(65.54–72.54). Approximately 43% of patients had a lower score at the follow-up visit (indicating a decreased ability to per-
form activities of daily living), 24% a higher score (indicating an increased ability), and 33% the same score at baseline and 
follow-up. The mean annual change in the DM1-ActivC total score, estimated at − 2.06 (− 3.54 to − 0.59), was significantly 
related to patients’ baseline score, but not sex, disease duration, timed test results, or cytosine-thymine-guanine repeat length.
Conclusions Change over time in ability to perform activities of daily living as recorded through the DM1-ActivC varies 
substantially between patients with DM1. Our data contribute to the understanding of the natural evolution of the disease, 
and should be helpful to inform the design of future trials based on the DM1-ActivC.
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Introduction
Myotonic dystrophy type 1 (DM1) is a progressive, yet 
highly heterogeneous multi-system disorder affecting muscle 
strength and mobility, amongst many other clinical domains 
[1]. Individually or collectively, these disease manifestations 
lead to impaired performance in daily life and restriction in 
social participation [2, 3]. The clinical variability of DM1, 
which partly has been attributed to the nature of the underly-
ing gene defect as expressed via unstable triplet repeats of 
the DMPK gene, makes the design of clinical trials in this 
indication challenging, particularly the identification and 
selection of outcome measures that are relevant and fit for 
purpose to measure drug benefits across the full spectrum 
of disease severity and morbidity [4, 5].
The DM1 activity and participation scale for clinical use 
(DM1-ActivC) is an outcome tool developed to measure abil-
ity to perform activities of daily living (e.g., taking a shower, 
visiting family or friends, and walking up a flight of stairs) in 
patients with DM1 [6, 7]. It was designated as the primary 
endpoint in a recently completed clinical trial of cognitive 
behavioral therapy with optional graded exercise therapy in 
patients with DM1 (i.e., the OPTIMISTIC trial) [8]. How-
ever, to date, no study has in detail examined changes over 
time in outcomes from the DM1-ActivC aside changes in 
total scale scores in patients with DM1. Accordingly, the 
objective of this study was to investigate natural changes 
over time in ability to perform activities of daily living as 
recorded using the DM1-ActivC in patients with DM1 in 
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the UK receiving no specific treatment. A specific aim was 
to examine the association between perceived performance 
at baseline, sex, disease duration, and cytosine-thymine-
guanine (CTG) repeat length, and change across follow-up, 
respectively.
Methods
Study design and patient sample
This was a longitudinal, observational study of patients 
with genetically confirmed DM1 recruited from Newcas-
tle University (Newcastle upon Tyne, UK) and University 
College London Hospitals NHS Foundation Trust (London, 
UK) as part of the Myotonic Dystrophy Type 1 Deep Phe-
notyping to Improve Delivery of Personalized Medicine and 
Assist in the Planning, Design and Recruitment of Clini-
cal Trials (PhenoDM1) study (ClinicalTrials.gov identifier: 
NCT02831504). The following inclusion criteria were 
imposed for patient study eligibility: (1) ≥ 18 years of age, 
(2) genetically confirmed diagnosis of DM1, and (3) ability 
to perform the 10 m walking test at selected pace without 
any assistance (walking devices allowed). All participants 
provided informed consent to participate in the study and 
ethical approval was granted by the Newcastle and North 
Tyneside Ethics Committee (reference: NE/15/0178).
Study procedures and outcomes
Eligible patients were asked to complete the DM1-ActivC as 
part of the study visits. The DM1-ActivC was initially devel-
oped in 2010 [6], but re-constructed in 2015 [7], and the cur-
rent version encompasses a total of 25 items, each described 
in three levels. The tool has been developed using modern 
psychometric analysis (i.e., Rasch analysis [9]) and has been 
shown to adhere to the epistemological requirements for sta-
ble measures, including linearity, invariance, and unidimen-
sionality [10, 11]. At baseline, we also recorded basic demo-
graphic and clinical characteristics (as listed in Table 1). The 
6-minute walk test (6MWT) was performed at baseline and 
follow-up in a 25-m long corridor in Newcastle and 20-m 
long corridor in London. Per currently agreed procedures 
[4], patients received feedback every minute of the current 
test time (i.e., the time left of the total 6-m test time).
Genetic analysis
Recent research [12] has shown that the length of the repeat 
expansion at birth as expressed by the progenitor allele is the 
most relevant predictor of disease onset and severity later 
in life, while disease progression is closely related to the 
rate of somatic expansion over time within different tissues 
(approximated as the difference between modal length at the 
time of DNA sampling and the progenitor allele, where the 
modal allele length is the most common repeat length in that 
tissue at time of sampling). For our analysis, to allow com-
parison of data, we included both CTG repeat counts from 
blood DNA (i.e., the estimated progenitor and modal allele 
length). CTG repeat length was estimated from blood DNA 
by the small-pool PCR assay as described by Gomes-Pereira 
et al. [13] using the CTG repeat-flanking primers DM-C 
and DM-DR [12, 14]. Replicate reactions were separated by 
gel electrophoresis, Southern blotted and hybridised using a 
32P-labelled 56 × CTG repeat probe. Bands were detected by 
autoradiography and sized by comparison against the DNA 
molecular weight marker, using CLIQS software (TotalLab 
UK Ltd.). The bottom edge of the expanded allele bands was 
used to determine the estimated progenitor allele length [12]. 
The densest part of the expanded allele bands was used to 
estimate the modal allele length at the time of DNA sam-
pling (i.e., CTG modal alleles). The CTG repeat length anal-
ysis was only available for patients recruited via Newcastle 
University, Newcastle upon Tyne.
Statistical analysis
We calculated the distribution of replies across all items and 
levels within the DM1-ActivC and the corresponding mean 
item scores, ranging from 0 (“Not possible to perform”) to 
2 (“Possible, without any difficulty”), as well as the mean 
transformed total instrument score (ranging between 0 and 
100, where a higher/lower score indicates a higher/lower 
ability to perform activities of daily living) at baseline 
and the follow-up visit. We related the total score to two 
previously derived [7] threshold values (amended for the 
transformed scale): ≤ 30 (indicating severe limitations in 
activities of daily living), and > 70 (indicating relatively 
few limitations). We calculated the unadjusted mean change 
in DM1-ActivC total scores from baseline to follow-up for 
the total sample, as well as for patients with a higher and 
lower score at the follow-up visit, respectively. To account 
for differences in follow-up length, we also derived unad-
justed mean annual changes in DM1-ActivC total scores 
(assuming a linear change over time in DM1-ActivC total 
scores at the patient level). We compared changes in DM1-
ActivC total scores by sex and type of DM1 defined based 
on age at onset of disease [congenital: ≤ 11 months; clas-
sical: 12 months–40 years; and late adult: > 40 years, with 
a Muscular Impairment Rating Scale (MIRS) score < III, 
and < 150 CTG repeats] using Welch’s t test. We also com-
pared demographic and clinical characteristics of patients 
with a lower DM1-ActivC total score at the follow-up (indi-
cating a decreased ability to perform activities of daily liv-
ing), a higher score (indicating an increased ability), and the 
same score using Welch’s analysis of variance (ANOVA) 
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models and Pearson’s Chi-square test. We estimated Pear-
son’s correlation coefficients to investigate the crude rela-
tionship between disease duration (measured from onset), 
CTG repeat length, MIRS score, and 6MWT result, respec-
tively, and annual changes in DM1-ActivC total scores. In 
addition, to further investigate the association between the 
baseline DM1-ActivC total score (which may serve as a 
meaningful and easily measurable criterion for future clini-
cal trials) and annual changes in total scores, we fitted an 
ordinary least squares linear regression model to our study 
data, with annual change in the DM1-ActivC total score as 
the dependent variable and the baseline score as the primary 
explanatory variable. To adjust for confounding effects, the 
model was specified to also include sex, age, and estimated 
progenitor CTG repeat length, as well as an interaction 
variable between estimated progenitor CTG repeat length 
(normalised by log transformation) and age, per previous 
research [12]. Robust standard errors were derived using 
the Huber/White/sandwich estimator. All analyses were con-
ducted in Stata 14 (StataCorp, College Station, TX, USA).
Results
A total of n = 213 patients with DM1 met all study inclu-
sion criteria and were enrolled into the PhenoDM1 study. 
Of these, n = 150 completed the DM1-ActivC in accordance 
with instructions at both the baseline and follow-up visit. 
Demographic and clinical characteristics of the sample 
are presented in Table 1. At baseline, less than half (41%, 
61 of 150) of all patients reported being employed (part-
time or full-time) and one-third (33%, 43 of 132) of those 
Table 1  Baseline demographic and clinical characteristics of the patient sample
Data presented as n (%), if not specified otherwise. Total sample size: an = 144; bn = 143; cn = 145; dn = 140; and en = 136. Because of rounding, 
percentages might not add up to 100% exactly
DM1 myotonic dystrophy type 1
†Comparing patients with a higher DM1-ActivC total score, same score, and lower score at follow-up
Total sample (n = 150) Lower total score
(i.e., worsened ability) 
at follow-up (n = 65)
Same total 
score at follow-
up (n = 49)
Higher total score
(i.e., improved ability) 
at follow-up (n = 36)
p value†
Age, mean (SD) years 45 (14) 50 (12) 39 (16) 46 (11) 0.001
Sex, female 78 (52%) 38 (58%) 24 (49%) 16 (44%) 0.352
Age at first symptoms, mean (SD)  yearsa 26 (17) 28 (18) 23 (17) 27 (16) 0.343
Disease duration, mean (SD)  yearb 20 (12) 22 (13) 16 (12) 20 (11) 0.090
Type of  DM1c
 Congenital 8 (5%) 2 (3%) 5 (11%) 1 (3%) 0.141
 Classical 101 (70%) 45 (70%) 29 (64%) 27 (75%) 0.583
 Late onset 36 (25%) 17 (27%) 11 (24%) 8 (22%) 0.888
Part-time wheelchair dependency 22 (15%) 10 (15%) 4 (8%) 8 (22%) 0.190
6-minute walk test
 Baseline result, mean (SD)  metersd 422 (152) 407 (129) 489 (155) 375 (137) 0.002
 Follow-up result, mean (SD)  meterse 404 (157) 356 (149) 491 (151) 368 (132)  < 0.001
 Δ (follow-up—baseline result)e − 30 (71) − 52 (82) − 14 (57) − 14 (56) 0.015
Muscular impairment rating scale (MIRS) score
 I 19 (13%) 7 (11%) 9 (18%) 3 (8%) 0.323
 II 40 (27%) 15 (23%) 20 (41%) 5 (14%) 0.015
 III 30 (20%) 15 (23%) 8 (16%) 7 (19%) 0.669
 IV 47 (31%) 22 (34%) 9 (18%) 16 (44%) 0.032
 V 14 (9%) 6 (9%) 3 (6%) 5 (14%) 0.477
Education, mean (SD) years  completedd 15 (3) 15 (3) 16 (3) 15 (3) 0.076
Current occupation
 Employed 61 (41%) 22 (34%) 26 (53%) 13 (36%) 0.096
 Retired 22 (15%) 10 (15%) 7 (14%) 5 (14%) 0.975
 Long-term sick leave 35 (23%) 17 (26%) 5 (10%) 13 (36%) 0.016
 Unemployed/other 32 (21%) 16 (25%) 11 (22%) 5 (14%) 0.440
Follow-up, mean (SD) days 383 (47) 382 (40) 393 (50) 373 (54) 0.202
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of working age (i.e., < 65 years) were retired or on long-
term sick leave. Mean estimated progenitor and modal allele 
length, based on data for 56% (84 of 150) and 55% (82 of 
150) of patients, respectively, were 234 CTG repeats (SD: 
171, range: 55–916) and 465 CTG repeats (344, 62–1441). 
In the subset of patients from the PhenoDM1 study analyzed 
as part of this work, three had variant repeat interruptions.
At baseline, the mean DM1-ActivC total score in our 
sample was estimated at 71.24 [SD: 21.53, range: 28–100, 
95% confidence interval (CI) 67.77–74.71]. Approximately 
1% (2 of 150) scored ≤ 30 (indicating severe limitations in 
activities of daily living), and 48% (72 of 150) scored > 70 
(indicating relatively few limitations). At follow-up, after 
a mean duration of 383 days, the mean DM1-ActivC total 
score in our sample was estimated at 69.04 (SD: 21.67, 
range: 25–100, 95% CI 65.54–72.54), with the same pro-
portions scoring ≤ 30 and > 70.
The unadjusted mean change in the DM1-ActivC total 
score during follow-up was estimated at − 2.20 (SD: 9.50, 
range: − 47 to 28, 95% CI − 3.73 to − 0.67). Approximately 
43% (65 of 150) of patients had a lower score at the follow-
up visit (indicating a decreased ability to perform activities 
of daily living), 24% (36 of 150) a higher score (indicating 
an increased ability), and 33% (49 of 150) the same score 
at baseline and follow-up. The mean unadjusted change in 
patients with a lower total score at follow-up was − 9.68 
(SD: 7.74, range: − 47 to − 1, 95% CI − 11.60 to − 7.76), 
and a higher total score 8.31 (SD: 7.13, range: 1–28, 95% CI 
5.89–10.72). Demographic and clinical characteristics of the 
three patient groups are presented in Table 1.
Accounting for the patient-specific length of follow-up, 
and assuming a linear change (at the patient level) in DM1-
ActivC total scores, the unadjusted mean annual change in 
the DM1-ActivC total score in the total sample population 
was − 2.06 (SD: 9.14, range: − 43.57 to 34.55, 95% CI 
− 3.54 to − 0.59) (Fig. 1). The corresponding estimate for 
patients with a lower total score at follow-up was − 9.25 (SD: 
7.26, range: − 43.57 to − 0.98, 95% CI − 11.05 to − 7.45), 
and a higher score 8.10 (SD: 7.14, range: 0.90–34.55, 95% 
CI 5.68–10.51). We found no significant differences between 
women and men in the unadjusted mean annual change in the 
DM1-ActivC total score across follow-up (− 2.24 vs. − 1.87, 
p = 0.808). The unadjusted mean annual change in the DM1-
ActivC total score was − 1.96 (SD: 9.25, range: − 43.57 to 
24.64, 95% CI − 3.79 to − 0.13) for patients with classical 
DM1, − 1.48 (SD: 7.32, range: − 17.18 to 9.13, 95% CI 
− 7.61 to 4.64) for congenital DM1, and − 2.69 (SD: 9.95, 
range: − 20.93–34.55, 95% CI − 6.06 to 0.68) for late onset 
DM1 (classical vs. congenital: p = 0.887; classical vs. late 
onset: p = 0.690; and congenital vs. late onset: p = 0.748). In 
patients with variant repeat interruptions (n = 3), the mean 
annual change in the DM1-ActivC total score was − 2.63 
(SD: 7.54, range: − 5.09–9.99, 95% CI − 16.12–21.37). 
Changes in scores were not significantly different across 
categories of current occupation (all p > 0.479).
Table 2 summarizes changes during follow-up to the indi-
vidual items within the DM1-ActivC for the total sample, as 
well as patients with a higher total score (i.e., an improved 
ability to perform activities of daily living) and lower total 
score (i.e., a worsened ability) at follow-up, respectively. For 
example, 86% (31 of 36) of patients who had a higher total 
score at the end of the follow-up provided the same answer 
at the baseline and follow-up visit to the question pertaining 
to their ability to eat soup. As shown in the table, replies to 
most items did not change from the baseline to the follow-up 
visit. For the subgroup with a higher total score at follow-up, 
the item with the largest positive change (i.e., an increased 
score from 0 to 1, or 1 to 2) was “Carry and put down heavy 
object (10 kg)”, where 44% (16 of 36) of patients indicated 
improvement in their ability, followed by “Serve coffee/tea 
on a tray” (42%, 15 of 36), and “Stand on one leg” (36%, 13 
of 36). Worsened ability (i.e., a decreased item score from 
2 to 1, or 1 to 0) for this subgroup of patients was first and 
foremost noted for “Stand up from squatting position” (17%, 
6 of 36), and “Dress your lower body” and “Wash your upper 
body” (14%, 5 of 36, respectively). For patients with a lower 
total score at follow-up, the largest improvement was noted 
for “Stand up from squatting position”, where 11% (7 of 
65) had a higher item score, followed by “Walk three flights 
of stairs” and “Carry and put down heavy object (10 kg)” 
(8%, 5 of 65, respectively). The largest loss in ability for 
this subgroup concerned “Stand up from squatting position”, 
where 38% (25 of 65) of patients had a lower item score 
at follow-up, followed by “Dance” (34%, 22 of 65). In the 
total sample, the item exhibiting the largest positive change 
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Fig. 1  Histogram of annual changes in DM1-ActivC total scores. A 
higher/lower score indicates a higher/lower ability to perform activi-
ties of daily living
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Table 2  Changes from baseline to follow-up to individual items within the DM1-ActivC
Data reported as n (%). Because of rounding, percentages might not add up to 100% exactly. In total, n = 49 patients had the same DM1-ActivC 
total score at baseline and the follow-up visit. A higher/lower score indicates a higher/lower ability to perform activities of daily living
Total sample
(n = 150)
Lower total score (i.e., worsened ability)
at follow-up (n = 65)
Higher total score (i.e., improved 
ability) at follow-up (n = 36)
No item
change
Higher item 
score at
follow-up
Lower item
score at 
follow-up
No item
change
Higher item
score at 
follow-up
Lower item
score at 
follow-up
No item
change
Higher item 
score at
follow-up
Lower item 
score at
follow-up
Eat soup 137 (91%) 7 (5%) 6 (4%) 58 (89%) 3 (5%) 4 (6%) 31 (86%) 3 (8%) 2 (6%)
Visit family or 
friends
129 (86%) 10 (7%) 11 (7%) 56 (86%) 2 (3%) 7 (11%) 26 (72%) 8 (22%) 2 (6%)
Care for your 
hair and body
129 (86%) 8 (5%) 13 (9%) 53 (82%) 2 (3%) 10 (15%) 29 (81%) 4 (11%) 3 (8%)
Dress your 
lower body
125 (83%) 7 (5%) 18 (12%) 52 (80%) 1 (2%) 12 (18%) 26 (72%) 5 (14%) 5 (14%)
Wash your 
upper body
128 (85%) 10 (7%) 12 (8%) 55 (85%) 3 (5%) 7 (11%) 27 (75%) 4 (11%) 5 (14%)
Take a shower 124 (83%) 12 (8%) 14 (9%) 53 (82%) 2 (3%) 10 (15%) 27 (75%) 7 (19%) 2 (6%)
Wash your 
lower body
127 (85%) 9 (6%) 14 (9%) 53 (82%) 1 (2%) 11 (17%) 27 (75%) 6 (17%) 3 (8%)
Get out of bed 120 (80%) 11 (7%) 19 (13%) 51 (78%) 0 (0%) 14 (22%) 29 (81%) 6 (17%) 1 (3%)
Move a chair 116 (77%) 14 (9%) 20 (13%) 52 (80%) 1 (2%) 12 (18%) 24 (67%) 9 (25%) 3 (8%)
Do the dusting/
cleaning
126 (84%) 9 (6%) 15 (10%) 52 (80%) 2 (3%) 11 (17%) 30 (83%) 6 (17%) 0 (0%)
Do the shop-
ping
126 (84%) 10 (7%) 14 (9%) 55 (85%) 0 (0%) 10 (15%) 27 (75%) 7 (19%) 2 (6%)
Tie the laces of 
your shoes
112 (75%) 11 (7%) 27 (18%) 42 (65%) 2 (3%) 21 (32%) 27 (75%) 7 (19%) 2 (6%)
Catch an object 
(e.g., a ball)
118 (79%) 16 (11%) 16 (11%) 48 (74%) 4 (6%) 13 (20%) 28 (78%) 6 (17%) 2 (6%)
Use dustpan 
and brush
111 (74%) 13 (9%) 26 (17%) 45 (69%) 2 (3%) 18 (28%) 22 (61%) 10 (28%) 4 (11%)
Empty dustbin 117 (78%) 12 (8%) 21 (14%) 46 (71%) 1 (2%) 18 (28%) 24 (67%) 10 (28%) 2 (6%)
Make up your 
bed
111 (74%) 14 (9%) 25 (17%) 47 (72%) 3 (5%) 15 (23%) 24 (67%) 9 (25%) 3 (8%)
Vacuum clean 119 (79%) 15 (10%) 16 (11%) 50 (77%) 1 (2%) 14 (22%) 27 (75%) 9 (25%) 0 (0%)
Serve coffee/
tea on a tray
111 (74%) 18 (12%) 21 (14%) 51 (78%) 0 (0%) 14 (22%) 20 (56%) 15 (42%) 1 (3%)
Dance 107 (71%) 17 (11%) 26 (17%) 40 (62%) 3 (5%) 22 (34%) 26 (72%) 8 (22%) 2 (6%)
Stand up from 
squatting 
position
95 (63%) 21 (14%) 34 (23%) 33 (51%) 7 (11%) 25 (38%) 21 (58%) 9 (25%) 6 (17%)
Stand on one 
leg
102 (68%) 18 (12%) 30 (20%) 44 (68%) 1 (2%) 20 (31%) 20 (56%) 13 (36%) 3 (8%)
Walk uphill 115 (77%) 8 (5%) 27 (18%) 44 (68%) 1 (2%) 20 (31%) 29 (81%) 6 (17%) 1 (3%)
Walk three 
flights of 
stairs
115 (77%) 15 (10%) 20 (13%) 46 (71%) 5 (8%) 14 (22%) 26 (72%) 8 (22%) 2 (6%)
Carry and 
put down 
heavy object 
(10 kg)
96 (64%) 28 (19%) 26 (17%) 39 (60%) 5 (8%) 21 (32%) 17 (47%) 16 (44%) 3 (8%)
Run 116 (77%) 16 (11%) 18 (12%) 46 (71%) 4 (6%) 15 (23%) 24 (67%) 11 (31%) 1 (3%)
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was “Carry and put down heavy object (10 kg)”, where 19% 
(28 of 150) had a higher item score at follow-up, followed 
by “Stand up from squatting position” (14%, 21 of 150), 
and “Serve coffee/tea on a tray” and “Stand on one leg” 
(12%, 18 of 150, respectively). The item with the largest 
negative change was “Stand up from squatting position”, 
where 23% (34 of 150) had a lower item score at follow-up, 
followed by “Stand on one leg” (20%, 30 of 150), and “Tie 
the laces of your shoes” and “Walk uphill” (18%, 27 of 150, 
respectively).
We found the annual change in the DM1-ActivC total 
score to be related to the total score at baseline (i.e., 
patients’ baseline ability to perform activities of daily liv-
ing) (p = − 0.20, p = 0.015), but not estimated progenitor or 
modal allele CTG repeat length (p = 0.937 and p = 0.897, 
respectively), disease duration (p = 0.712), or baseline MIRS 
or 6MWT result (p = 0.901 and p = 0.567, respectively). 
Results from our regression analysis revealed that each 
ten-point change in the DM1-ActivC total score at baseline 
was associated with a mean annual total score change of 
− 1.37 (SE: 0.66, 95% CI − 2.68 to − 0.06, p = 0.041) when 
adjusting for age, sex, and estimated progenitor CTG repeat 
length (full model results available as supplemental mate-
rial online).
Discussion
The objective of this study was to investigate change over 
time in ability to perform activities of daily living as meas-
ured using the DM1-ActivC in patients with DM1. Taken 
together, our results reveal substantial heterogeneity in 
changes across follow-up in DM1-ActivC total scores at 
the population level. Indeed, almost half of our sample 
(43%) had a lower score at the follow-up visit (indicating a 
decreased ability to perform activities of daily living), 24% 
a higher score (indicating an increased ability), and 33% 
the same score at baseline and follow-up. Results from the 
6MWT were distributed in line with these findings, show-
ing a markedly greater decline for those with a lower DM1-
ActivC total score at the follow-up. In addition, we found 
baseline ability to perform activities of daily living to be sig-
nificantly associated with annual change in total scores, but 
not sex, disease duration, timed test results, or CTG repeat 
length. These data should be helpful to inform the design of 
future studies based on the DM1-ActivC.
Comparing our results with previous research, changes in 
DM1-ActivC total scores have been estimated and reported 
as part of the OPTIMISTIC trial in patients with DM1 with 
severe fatigue [8]. In that study, the unadjusted mean change 
in the total score across follow-up (comprising 10 months) 
for patients receiving cognitive behavioral therapy with 
optional graded exercise therapy (n = 128; mean age: 
45 years; 45% female) was estimated at 2.70. For patients 
receiving standard of care (n = 127; mean age: 46 years; 47% 
female), the mean change was − 2.21. Adjusting our esti-
mates to reflect the same follow-up duration, the unadjusted 
mean change in the DM1-ActivC total score in our sample 
was − 1.72 (95% CI − 2.95 to − 0.49). However, it should 
be emphasized that these studies are not directly comparable 
due to non-trivial differences concerning demographic and 
clinical characteristics of the sample populations.
We found that replies to only a limited set of items 
changed from baseline to end of follow-up (Table 2). Spe-
cifically, in the total sample, replies to only three individual 
items changed during follow-up for > 30% of patients, and 15 
items for > 20%. Moreover, changes to replies to all but two 
items, namely “Eat soup” and “Carry and put down heavy 
object (10 kg)”, were indicative of lost ability (i.e., a net 
negative change in item scores). Notable examples of items 
for which a larger proportion of patients with any change 
had a lower as opposed to higher score at follow-up include 
“Walk uphill” (18% vs. 5%), “Tie the laces of your shoes” 
(18% vs. 7%) and “Stand up from squatting position” (23% 
vs. 14%). Looking at the subset of patients with a higher 
total score at follow-up, items with the largest positive 
change were “Carry and put down heavy object (10 kg)”, 
“Serve coffee/tea on a tray”, and “Stand on one leg”. To our 
surprise, 44% of these patients indicated an improvement in 
their ability to “Carry and put down heavy object (10 kg)” 
across follow-up. Furthermore, for this subgroup, the only 
items where > 10% of patients had a lower score at follow-up 
were “Stand up from squatting position”, “Use dustpan and 
brush”, “Dress your lower body”, and “Wash your upper 
body”. The items with the largest negative change in the 
group of patients with a lower total score at follow-up were 
“Stand up from squatting position” and “Dance”. Indeed, 
for these two items, more than one-third of patients had a 
lower item score at the end of follow-up. Only one item 
(“Stand up from squatting position”) had a positive change 
in > 10% of patients in this subgroup. Taken together, these 
data show that change over time in ability to perform activi-
ties of daily living as recorded using the DM1-ActivC is 
highly variable in DM1, and that changes (negative, as well 
as positive) seem to involve gross and fine motor skills of 
both the upper and lower extremities. In terms of measur-
ing annual change, our analysis also reveals that some items 
appear to be lacking relevance at the population level with 
respect to the underlying, highly variable natural evolution 
of the disease. More research is needed to fully understand 
these properties of the DM1-ActivC.
The minimal clinically important difference in DM1-
ActivC total scores is yet to be estimated. For this reason, 
it is not straightforward to interpret the magnitude of the 
annual changes reported as part of this work. Still, consid-
ering that a one-point change at the item level means that a 
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specific task no longer can be performed without difficulty, 
or at all, and given the fact that items within the DM1-ActivC 
captures common activities of daily living involving signifi-
cant muscle function, it could be argued that even a one-
point change would be meaningful from the perspective of 
the individual patient.
As mentioned in brief above, results from our adjusted 
regression analysis showed that the baseline DM1-ActivC 
total score was significantly associated with the annual 
change in total score. Specifically, we found that patients 
with a higher score at baseline had a larger negative change 
across follow-up when controlling for age, sex, and esti-
mated progenitor CTG repeat length. Although a diminish-
ing marginal loss in ability in relation to the initial level 
of ability may appear intuitive (i.e., the more ability you 
possess, the more you can theoretically lose over time), this 
result would be expected to be of importance when design-
ing trials involving the DM1-ActivC. In particular, our data 
suggests that it may be challenging to conduct meaning-
ful measurement of changes in ability to perform activities 
of daily living over time using the DM1-ActivC in patient 
populations characterized by a low starting level of ability. 
That being said, it is important to keep in mind that addi-
tional research is needed to confirm our findings, preferably 
in a larger sample with an even greater diversity of ability 
at baseline.
The main limitation of our study concerns the precision 
and external validity of our results due to the relatively small 
number of patients in comparison with research of more 
common illnesses. Yet, it should be noted that our sample of 
150 patients is large in the context of studies in DM1 [15]. 
In addition, the DM1-ActivC data may be subject to bias due 
to, for example, incorrect reporting. This issue would be 
expect to be of particular relevance in populations character-
ized by some degree of cognitive impairment, such as DM1. 
However, per the study procedures, patients with significant 
cognitive impairment were not eligible to participate, which 
should help minimize errors associated with the data collec-
tion. Another potential source of variability across follow-up 
includes learning effects, where patients’ experience of the 
DM1-ActivC at baseline may influence their assessment at 
follow-up [4, 16]. We were also unable to unable to infer 
causality behind identified associations due to the obser-
vational nature of our data. Finally, when interpreting our 
regression analysis results, it is important to keep in mind 
that the estimated coefficients may be subject to unmeasured 
confounding.
In conclusion, we show that change over time in abil-
ity to perform activities of daily living as recorded through 
the DM1-ActivC varies substantially between patients with 
DM1. Our data contribute to the understanding of the natural 
evolution of the disease, and should be helpful to inform the 
design of future trials based on the DM1-ActivC.
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